T. Rowe Price Associates
LUNG icon

T. Rowe Price Associates’s Pulmonx LUNG Stock Holding History

T. Rowe Price Associates’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,884
Closed -$26K – 3295
2026
Q1 		$26K Hold
19,884
– – ﹤0.01% 3109
2025
Q4 		$44K Hold
19,884
– – ﹤0.01% 3044
2025
Q3 		$33K Sell
19,884
-17,846
-47% -$37.3K ﹤0.01% 3026
2025
Q2 		$98K Buy
37,730
+1,588
+4% +$6.26K ﹤0.01% 2896
2025
Q1 		$244K Buy
36,142
+2,557
+8% +$18.1K ﹤0.01% 2551
2024
Q4 		$229K Sell
33,585
-9,423
-22% -$62K ﹤0.01% 2626
2024
Q3 		$357K Buy
43,008
+299
+0.7% +$2.16K ﹤0.01% 2401
2024
Q2 		$271K Buy
42,709
+6,989
+20% +$53.7K ﹤0.01% 2462
2024
Q1 		$332K Buy
35,720
+1,633
+5% +$19.1K ﹤0.01% 2390
2023
Q4 		$435K Buy
34,087
+580
+2% +$6.04K ﹤0.01% 2236
2023
Q3 		$347K Buy
33,507
+3,749
+13% +$43.4K ﹤0.01% 2280
2023
Q2 		$391K Buy
29,758
+2,963
+11% +$36.2K ﹤0.01% 2247
2023
Q1 		$300K Buy
26,795
+691
+3% +$6.82K ﹤0.01% 2343
2022
Q4 		$220K Buy
26,104
+708
+3% +$6.73K ﹤0.01% 2492
2022
Q3 		$424K Buy
25,396
+2,033
+9% +$37.4K ﹤0.01% 2210
2022
Q2 		$344K Buy
23,363
+2,377
+11% +$49K ﹤0.01% 2387
2022
Q1 		$521K Sell
20,986
-197
-0.9% -$5.09K ﹤0.01% 2321
2021
Q4 		$679K Sell
21,183
-390,204
-95% -$14.3M ﹤0.01% 2235
2021
Q3 		$14.8M Buy
411,387
+21,860
+6% +$860K ﹤0.01% 1366
2021
Q2 		$17.2M Sell
389,527
-328,396
-46% -$14.3M ﹤0.01% 1335
2021
Q1 		$32.8M Buy
717,923
+348,008
+94% +$20M ﹤0.01% 1149
2020
Q4 		$25.5M Buy
+369,915
New +$18.1M ﹤0.01% 1159

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates's LUNG Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Pulmonx (LUNG) in Q2 2026, closing a stake of 19,884 shares — an estimated $26K sold.

T. Rowe Price Associates first reported a position in LUNG in Q4 2020 and held it in 22 quarters. The position peaked at $32.8M in Q1 2021. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • T. Rowe Price Associates reported no remaining Pulmonx position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 19,884 Pulmonx shares in Q2 2026, an estimated $26K.
  • T. Rowe Price Associates first reported a position in Pulmonx in Q4 2020 and held it in 22 quarters.
  • T. Rowe Price Associates's Pulmonx position peaked at $32.8M in Q1 2021.
  • 108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.